Aided by our rich experience and professional scientists, Creative Biolabs has completed a series of challenges in the past years. In particular, we have established an advanced Bacteroides fragilis platform which enables us to offer a series of high-quality services for our worldwide customers. Meanwhile, our scientists specialized in live biotherapeutics drug discovery will work with you to develop the most appropriate strategy that will offer the most meaningful data for your research.
Bacteroides fragilis belongs to the family Bacteroidaceae. It is a gram-negative bacterium that is strongly associated with peritoneal infections and is the main cause of bacteremia and malignant tumors in humans. Pilot studies have shown that it is a common type of microorganism in humans and is usually symbiotic. Meanwhile, many studies have also revealed that Bacteroides fragilis can lead to different levels of infections when the tissue barrier is broken during surgery or trauma. Moreover, recent researchers have indicated that Bacteroides fragilis outer-membrane vesicles (OMVs) have been considered as a suitable delivery system for the transportation of biochemical substances. Also, several strains of Bacteroides fragilis, such as enterotoxigenic Bacteroides fragilis (ETBF) strain, have been isolated from different human colon samples. The data have suggested that these strains play an important role in various human diseases.
Bacteroides fragilis has proven its essential role as a friendly commensal in humans. The data have demonstrated that Bacteroides fragilis can regulate the expression level of bradykinin in human, suggesting it could be a next-generation probiotic (NGPs) for treating thrombotic diseases. Furthermore, many reports have shown that ETBF strains of Bacteroides fragilis can produce specific enterotoxin and may be beneficial to the treatment of diseases. As a result, a variety of Bacteroides fragilis-based and Bacteroides fragilis-targeted therapies have been generated for designing modified live biotherapeutics targeting a wide spectrum of clinical applications.
Fig.1 This micrograph depicts Bacteroides fragilis bacteria cultured in blood agar medium for 48 hours.
Nowadays, Creative Biolabs has established a comprehensive next-generation probiotics (NGPs) discovery platform based on Bacteroides fragilis for the developing novel live biotherapeutics drugs for the treatment of diseases, including but not limited to:
Inflammatory bowel disease (IBD) is a class of inflammatory diseases that often involves long-term inflammation of the digestive tract. Till now, many kinds of IBD, such as Crohn's disease, have been broadly studied, and the results have illustrated that the dysfunction of the immune system should be the main cause of human IBD. In the past few years, anti-inflammatory drugs, such as mesalamine, sulfasalazine, have been used as standard therapy for IBD. Recently, since ETBF strain has been isolated from patients with IBD, Bacteroides fragilis has been regarded as a perfect NGP candidate in the clinic.
Evidence has shown that Bacteroides fragilis can play a protecting role in treating colorectal cancer (CRC) by mediating immune responses and regulating the level of epithelial cells. Meanwhile, Bacteroides fragilis can prevent the expression of specific chemokine receptors (CCR5) and produce polysaccharide A against CRC in mice models. Therefore, Bacteroides fragilis has been used to inhibit CRX-associated tumorigenesis and tumor formation and may provide a unique therapeutic opportunity for CRC treatment.
Fig.2 Colonization with Bacteroides fragilis protects mice against the development of colon cancer. (Lee, 2018)
As a global CRO company, Creative Biolabs is well-equipped to handle almost any project of Bacteroides fragilis-based haptens regardless of scope or complexity. We have integrated the key components of early development to ensure that programs advance while meeting any special requirement with the flexibility to address dynamic challenges. For more information, please feel free to contact us or send us an inquiry.
|CAT||Product Name||Product Overview|
|LBST-013FG||Bacteroides fragilis; VPI 2553||Bacteroides fragilis was isolated from appendix abscess. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.|
|LBST-014FG||Bacteroides fragilis; 37758||Bacteroides fragilis was isolated from human blood. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.|
|LBST-015FG||Bacteroides fragilis; 36926||Bacteroides fragilis was isolated from human blood. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.|
|LBST-016FG||Bacteroides fragilis; 36902||Bacteroides fragilis was isolated from human perianal abscess. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.|
|LBST-017FG||Bacteroides fragilis; 35671||Bacteroides fragilis was isolated from human tube. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.|
|LBST-018FG||Bacteroides fragilis; 25931||Bacteroides fragilis was isolated from human pleural fluid. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.|
|LBST-019FG||Bacteroides fragilis; 49424||Bacteroides fragilis was isolated from human blood. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.|
|LBST-020FG||Bacteroides fragilis; B56-3||Bacteroides fragilis was isolated from sewage water. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.|
|LBST-021FG||Bacteroides fragilis; 20793-3||Bacteroides fragilis was isolated from infant with diarrhea. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.|
|LBST-022FG||Bacteroides fragilis; 23745||Bacteroides fragilis was isolated from pleural fluid. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.|
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.